Epidarex Portfolio News

20 Nov

140

Apellis Pharmaceuticals to Acquire Potentia Pharmaceuticals.

In Portfolio

CRESTWOOD, KY November 20, 2014 – Apellis Pharmaceuticals Inc. Complement inhibition is the only mechanism thus far to show reductions in the growth of dry AMD. Potentia was the first company to develop a complement inhibitor for the treatment of AMD. APL-2 has the same…

18 Feb

243

Epidarex Capital Invests in Cancer Drug Developer Confluence Life Sciences Inc

In Portfolio

Bethesda, MD, February 18, 2014 – Epidarex Capital, a leading international early-stage life science venture capital fund, has invested in Confluence Life Sciences Inc., a biotechnology company focused on the rapid discovery and development of drugs to address unmet needs in cancer and chronic inflammatory…

06 Feb

263

Epidarex Capital Leads New Investment in Edinburgh Molecular Imaging

In Portfolio

Edinburgh, United Kingdom, February 7, 2014.  Epidarex Capital, a leading international early-stage life science venture capital fund, has announced a £4 million Series A investment, in Edinburgh Molecular Imaging (EMI). Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the round. EMI, an…

21 Aug

254

Apellis Pharmaceuticals Inc. Raises Series C Financing

In Portfolio

Louisville, Kentucky – August 21st, 2013 – Rock Spring Ventures has increased its investment in Apellis Pharmaceuticals Inc., an early-stage biotechnology company focused on developing a novel pipeline of anti-inflammatory products through a combination of in-licensing of preclinical compounds and in-house research and development. Apellis…